Sept. 5, 2007
Cisbio, Redwood City, Calif, a global developer of Homogeneous Time-Resolved Fluorescence (HTRF) technology and services used in assay development and drug screening, and Lumiphore Inc, Bagnols-sur-Ce’ze, France, an early-stage biotech company developing proprietary lanthanide technology for use in high-value applications, have signed an exclusive agreement for the incorporation of Lumiphore’s Lumi4 complexes in Cisbio assays.
Under the agreement, Cisbio holds the exclusive rights to apply Lumi4 technology to current and future research and development initiatives in Time-Resolved Fluorescence Resonance Energy Transfer-based (TR-FRET) assays for drug discovery. Lumi4 compounds bring photophysical properties, increased sensitivity and stability to TR-FRET assays for high-throughput screening (HTS) applications and the growing homogeneous assay market. The incorporation of these compounds to Cisbio’s proprietary HTRF technology has the potential to enable the development of a second generation of assay platforms used in HTS, particularly in the fields of GPCR (G-Protein Coupled Receptors) and kinase screening, according to the companies.
